
Starling Oncology, Inc.: shareholders and insiders
Price
$3.20
November 18, 2026Market cap $316M
What Ploutos Investor adds for Starling Oncology
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 52% since Nov 5, 2026, when the 10-Q these figures come from was filed ($6.70 then, $3.20 on Nov 18, 2026). The figures date from before that move.10-Q
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Nov 17, 2026, from their own Form 4 filings.
Bought on the market
$2.9M
1 person
Sold on the market
$14M
5 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan18%
- The rest82%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $2.9M by 1 person·sold $14M by 5 people
- 2025: no buys, sold $50.3K by 1 person
- 2026: bought $2.9M by 1 person, sold $14M by 5 people
- Nov 12, 2026Yale PodnosChief Medical OfficerKind
- Nov 9, 2026Jorey ChernettKind
- Nov 6, 2026Jorey ChernettKind
- Aug 21, 2026Brad HivelyDirectorKind10b5-1
- Aug 14, 2026Jorey ChernettKind
- Jul 27, 2026Mohit KaushalDirectorKind
- Jul 27, 2026Anne McGeorgeDirectorKind
- Jul 27, 2026Mark L PacalaDirectorKind
- Jul 27, 2026Mark StolperDirectorKind
- Jul 27, 2026Kimberly Jo TzoumakasDirectorKind
- Jul 27, 2026Brad HivelyDirectorKind
- Jul 27, 2026Karen Marie JohnsonDirectorKind
- Jul 21, 2026Jorey ChernettKind
- Jul 14, 2026Yale PodnosChief Medical OfficerKind10b5-1
- Jul 14, 2026Yale PodnosChief Medical OfficerKind10b5-1
- Jul 14, 2026Yale PodnosChief Medical OfficerKind10b5-1
- Jul 14, 2026Yale PodnosChief Medical OfficerKind10b5-1
- Jul 10, 2026Jorey ChernettKind
- Jul 7, 2026Kimberly Jo TzoumakasDirectorKind
- Jul 7, 2026Mark StolperDirectorKind
- Jun 23, 2026Jorey ChernettKind
- Jun 8, 2026Yale PodnosChief Medical OfficerKind10b5-1
- Jun 4, 2026Jorey ChernettKind
- May 20, 2026Jorey ChernettKind
- May 19, 2026Jorey ChernettKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | Yale PodnosChief Medical Officer | 770 | $3.76 | $2.9K | Form 4 | |
| Nov 9, 2026 | Jorey Chernett | 48.3K | $3.65 | $176.3K | Form 4 | |
| Nov 6, 2026 | Jorey Chernett | 2.85M | $3.99 | $11M | Form 4 | |
| Aug 21, 2026 | Brad HivelyDirector | 10b5-1 | 298.9K | $6.51 | $1.9M | Form 4 |
| Aug 14, 2026 | Jorey Chernett | 12.0K | $6.54 | $78.5K | Form 4 | |
| Jul 27, 2026 | Mohit KaushalDirector | 33.1K | – | – | Form 4 | |
| Jul 27, 2026 | Anne McGeorgeDirector | 41.2K | – | – | Form 4 | |
| Jul 27, 2026 | Mark L PacalaDirector | 30.1K | – | – | Form 4 | |
| Jul 27, 2026 | Mark StolperDirector | 31.1K | – | – | Form 4 | |
| Jul 27, 2026 | Kimberly Jo TzoumakasDirector | 29.1K | – | – | Form 4 | |
| Jul 27, 2026 | Brad HivelyDirector | 27.1K | – | – | Form 4 | |
| Jul 27, 2026 | Karen Marie JohnsonDirector | 31.1K | – | – | Form 4 | |
| Jul 21, 2026 | Jorey Chernett | 18.0K | $5.27 | $94.9K | Form 4 | |
| Jul 14, 2026 | Yale PodnosChief Medical Officer | 10b5-1 | 18.0K | $1.87 | $33.6K | Form 4 |
| Jul 14, 2026 | Yale PodnosChief Medical Officer | 10b5-1 | 18.0K | $6.43 | $115.6K | Form 4 |
| Jul 14, 2026 | Yale PodnosChief Medical Officer | 10b5-1 | 5,478 | $2.00 | $11.0K | Form 4 |
| Jul 14, 2026 | Yale PodnosChief Medical Officer | 10b5-1 | 5,478 | $6.35 | $34.8K | Form 4 |
| Jul 10, 2026 | Jorey Chernett | 15.0K | $5.85 | $87.8K | Form 4 | |
| Jul 7, 2026 | Kimberly Jo TzoumakasDirector | 17.2K | – | – | Form 4 | |
| Jul 7, 2026 | Mark StolperDirector | 25.8K | – | – | Form 4 | |
| Jun 23, 2026 | Jorey Chernett | 18.0K | $5.02 | $90.4K | Form 4 | |
| Jun 8, 2026 | Yale PodnosChief Medical Officer | 10b5-1 | 23.5K | $5.38 | $126.1K | Form 4 |
| Jun 4, 2026 | Jorey Chernett | 12.0K | $4.75 | $57.0K | Form 4 | |
| May 20, 2026 | Jorey Chernett | 33.5K | $4.07 | $136.3K | Form 4 | |
| May 19, 2026 | Jorey Chernett | 5,000 | $4.05 | $20.3K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 5, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by STLN's officers and directors from 2021 up to November 18, 2025, 5 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Chernett JoreyShare of class10.2%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Chernett Jorey | 10.2% | 10.12M | Mar 16, 20262 filings since Jan 15, 2026 | 13G/A |
Fell to 5% or less (4)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Renaissance TechnologiesIn the quarter-14%
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter+11%
- Millennium Mgmt (Englander)In the quarter+546%
- AQR CapitalIn the quarter+11%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Renaissance Technologies | 1.18M | -14% | $7.4M | 0.01% |
| Point72 (Cohen) | 411.6K | $2.6M | 0.00% | |
| Citadel Advisors (Griffin) | 992.9K | +11% | $6.3M | 0.00% |
| Millennium Mgmt (Englander) | 625.5K | +546% | $4.0M | 0.00% |
| AQR Capital | 53.8K | +11% | $300.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 6.61% of its shares outstanding were held short, -3.8% since the report before.
- Shares held short
- 6.54M
- 6.61%
- Since the report before6.79M on Sep 30, 2026
- -3.8%
- 5.6
- 1.16M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 67%
- Report date
- Oct 15, 2026
- Shares held short
- Aug 14, 2026: Shares held short 6.88M
- Aug 31, 2026: Shares held short 6.82M
- Sep 15, 2026: Shares held short 7.05M
- Sep 30, 2026: Shares held short 6.79M
- Oct 15, 2026: Shares held short 6.54M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading22.1% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 22.1% of the shares in the reported trades were short sales, against 59.3% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 22.1%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 59.3%
- Change
- -37.2 pts
- Short sales a dayon average, of 2.98M shares
- 659.4K
- More than atof 3,656 US-listed companies, same days
- 1%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 66.6%
- Oct 13, 2026: Short sales 36.4%
- Oct 14, 2026: Short sales 44.5%
- Oct 15, 2026: Short sales 54.5%
- Oct 16, 2026: Short sales 50.7%
- Oct 19, 2026: Short sales 73%
- Oct 20, 2026: Short sales 58.4%
- Oct 21, 2026: Short sales 81%
- Oct 22, 2026: Short sales 65.1%
- Oct 23, 2026: Short sales 72.8%
- Oct 26, 2026: Short sales 53.5%
- Oct 27, 2026: Short sales 62.5%
- Oct 28, 2026: Short sales 62%
- Oct 29, 2026: Short sales 62.9%
- Oct 30, 2026: Short sales 67.6%
- Nov 2, 2026: Short sales 70.4%
- Nov 3, 2026: Short sales 68.8%
- Nov 4, 2026: Short sales 61.4%
- Nov 5, 2026: Short sales 64.7%
- Nov 6, 2026: Short sales 22.7%
- Nov 9, 2026: Short sales 23.6%
- Nov 10, 2026: Short sales 18.4%
- Nov 11, 2026: Short sales 30.4%
- Nov 12, 2026: Short sales 18%
- Nov 13, 2026: Short sales 5.7%
- Nov 16, 2026: Short sales 30.7%
- Nov 17, 2026: Short sales 19.7%
- Nov 18, 2026: Short sales 24.6%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- M33 Growth I GP LLCDirector,TenPercentOwnerDirectly7.93M
- Jorey ChernettTenPercentOwnerDirectly7.86M
- Richard A BaraschDirectorDirectly–
- Daniel VirnichChief Executive OfficerDirectly724.4K
- Brad HivelyDirectorDirectly412.0K
- Anne McGeorgeDirectorDirectly332.5K
- Mihir ShahChief Financial OfficerDirectly327.6K
- Karen Marie JohnsonDirectorDirectly319.4K
- Mark L PacalaDirectorDirectly61.9K
- Yale PodnosChief Medical OfficerDirectly258.8K
- Robert Ross CarterChief Financial OfficerDirectly235.1K
- Mohit KaushalDirectorDirectly205.7K
- Jeremy CastleChief Operating OfficerDirectly90.4K
- Mark StolperDirectorDirectly57.0K
- Toi Hc I, LlcTenPercentOwnerDirectly–
- Kimberly Jo TzoumakasDirectorDirectly46.3K
- Havencrest Healthcare Partners, L.P.TenPercentOwnerDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| M33 Growth I GP LLCDirector,TenPercentOwner | 7.93M | 590.9K | Sep 4, 2025 | Form 4 |
| Jorey ChernettTenPercentOwner | 7.86M | – | Nov 9, 2026 | Form 4 |
| Richard A BaraschDirector | – | 1.78M | Mar 26, 2025 | Form 4 |
| Daniel VirnichChief Executive Officer | 724.4K | – | Mar 26, 2025 | Form 4 |
| Brad HivelyDirector | 412.0K | – | Aug 21, 2026 | Form 4 |
| Anne McGeorgeDirector | 332.5K | – | Jul 27, 2026 | Form 4 |
| Mihir ShahChief Financial Officer | 327.6K | – | Dec 14, 2023 | Form 4 |
| Karen Marie JohnsonDirector | 319.4K | – | Jul 27, 2026 | Form 4 |
| Mark L PacalaDirector | 61.9K | 225.0K | Jul 27, 2026 | Form 4 |
| Yale PodnosChief Medical Officer | 258.8K | – | Nov 12, 2026 | Form 4 |
| Robert Ross CarterChief Financial Officer | 235.1K | – | Jan 2, 2026 | Form 4 |
| Mohit KaushalDirector | 205.7K | – | Jul 27, 2026 | Form 4 |
| Jeremy CastleChief Operating Officer | 90.4K | – | Mar 26, 2025 | Form 4 |
| Mark StolperDirector | 57.0K | – | Jul 27, 2026 | Form 4 |
| Toi Hc I, LlcTenPercentOwner | – | 52.4K | Jan 23, 2024 | Form 4 |
| Kimberly Jo TzoumakasDirector | 46.3K | – | Jul 27, 2026 | Form 4 |
| Havencrest Healthcare Partners, L.P.TenPercentOwner | – | – | Jan 29, 2024 | Form 4 |
A lower bound: it counts only the 17 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
2 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 108
- Q4 2025: Managers 117
- Q1 2026: Managers 115
- Q2 2026: Managers 120
Institutional investors by quarter
The fund managers holding STLN, quarter by quarter, from Q3 2021 to Q2 2025, 16 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 120 managers held 40.09M shares, worth $218M. During the quarter 27 opened a position, 22 closed one, 49 added and 25 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+7.5%
- Deerfield ManagementIn the quarter
- Vanguard Capital ManagementIn the quarter-6.1%
- Josh Arnold Investment ConsultantIn the quarter
- Geode Capital ManagementIn the quarter+8.1%
- Goldman Sachs GroupIn the quarter+28%
- Wexford CapitalIn the quarter
- State StreetIn the quarter+6.3%
- NuveenIn the quarter×14.8
- Renaissance TechnologiesIn the quarter+51%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 4.75M | +7.5% | $26M |
| Deerfield Management | 3.36M | $18M | |
| Vanguard Capital Management | 3.27M | -6.1% | $18M |
| Josh Arnold Investment Consultant | 2.46M | $13M | |
| Geode Capital Management | 1.90M | +8.1% | $10M |
| Goldman Sachs Group | 1.74M | +28% | $9.4M |
| Wexford Capital | 1.71M | $9.3M | |
| State Street | 1.55M | +6.3% | $8.4M |
| Nuveen | 1.41M | ×14.8 | $7.6M |
| Renaissance Technologies | 1.37M | +51% | $7.4M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Starling Oncology's filings show?
Who buys and sells is one part of Starling Oncology's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have STLN's insiders bought or sold?
From Jun 5, 2026 to Nov 17, 2026 Starling Oncology's insiders bought $584.7K and sold $14M of shares on the market. 16% of the sales were under set 10b5-1 plans.
Which well-known managers hold STLN?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $7.4M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.